MedTrace Logo

Lymph Node Involvement Using Extended Pelvic Lymphadenectomy in Clinically Localized Prostate Cancer

NCT02156414 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 135

Last updated 2015-04-22

No results posted yet for this study

Summary

Prostate cancer is considered the fourth most common malignancy cancer in America. However, in Colombia the incidence is higher, and it is considered the second cause of death among men for malignance diseases. In the framework of clinical localized prostate cancer there is a controversy regarding the best predictors of risk and the best treatment options. The actual literature is discussing the possibility of underestimate the disease and actual tools are not sufficient for proper characterization. Is in this context that extended pelvic lymphadenectomy emerges as a stratification tool in prostate cancer that defines the real commitment of the disease. The investigators need to know the characteristics that the disease has on the investigators community so the investigators can generate appropriate therapeutic approach. Thus, the present prospective observational-descriptive multicenter study, want to determine in three referral centers in Bogotá Colombia , the frequency of pelvic node involvement in patients with localized clinical prostate cancer from the stratification achieved by pelvic lymphadenectomy extended.

Conditions

  • Secondary Malignant Neoplasm of Lymph Node
  • Prostatic Neoplasms

Interventions

PROCEDURE

Radical Prostatectomy

Radical Prostatectomy

PROCEDURE

Extended Lymphadenectomy

Extended Lymphadenectomy

Sponsors & Collaborators

  • Hospital Universitario San Ignacio

    collaborator OTHER

  • Fundación Santa Fe de Bogota

    collaborator OTHER

  • Fundación Cardioinfantil Instituto de Cardiología

    collaborator OTHER

  • Javeriana University

    lead OTHER

Principal Investigators

  • JOSE G RAMOS, MF · Javeriana University

  • JUAN G CATAÑO, MD · Javeriana University

  • LUIS G VILLARRAGA, MD · Javeriana University

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • Colombia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02156414 on ClinicalTrials.gov